Skip to main content
SpringerLink
Log in

Risperidone and Paliperone in the Treatment of Psychosis

  • Reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 37 Accesses

Abstract

Risperidone is a second-generation (atypical) antipsychotic drug used worldwide for positive symptoms of schizophrenia mainly. Beside oral and parenteral forms, a long-acting depot formulation as an injection every 4 weeks is also available. As a high-potency antipsychotic acting as D2 receptor antagonist, it tends to produce significant extrapyramidal side effects. The efficacy in treatment of psychoses was established in numerous randomized, double-blind, placebo-controlled studies, and maintenance studies.

Paliperidone, the active metabolite of risperidone, is approved for the short- and long-term treatment of schizophrenia in adults and adolescents as well as for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants. There are some advantages compared to risperidone, so it is recommended in patients with hepatic impairment and evokes less drug-drug interactions. A long-acting depot formulation as an injection every 3 months is also available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alphs L, Benson C, Cheshire-Kinney K, Lindenmyer JP, Mao L, Rodriguez SC, et al. Real world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76:554–61.

    Article  PubMed  Google Scholar 

  • Bitter I, Katona L, Zambori J, et al. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol. 2013;23:1383–90.

    Article  CAS  PubMed  Google Scholar 

  • Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind trial. Am J Psychiatry. 1998;155:499–504.

    Article  CAS  PubMed  Google Scholar 

  • Bouchard RH, Merette C, Pourcher E, et al. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. J Clin Psychopharmacol. 2000;20:295–304.

    Article  CAS  PubMed  Google Scholar 

  • Chue P, Chue J. A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder. Ther Clin Risk Manag. 2016;12:109–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the manage-ment of schizophrenia. Drugs. 2010;70:1295–317.

    Article  CAS  PubMed  Google Scholar 

  • Conley RR. Risperidone side effects. J Clin Psychiatry. 2000;61(Suppl 8):20–3. discussion 24-5

    CAS  PubMed  Google Scholar 

  • Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R D. 2015;15:163–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol fort he prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16–22.

    Article  CAS  PubMed  Google Scholar 

  • de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80–8.

    Article  PubMed  Google Scholar 

  • Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm. 2008;65:403–13.

    Article  CAS  PubMed  Google Scholar 

  • Dove D, Warren Z, McPheeters ML, Taylor JL, et al. Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics. 2012;130:717–26.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol. 2015;116:315–20.

    Article  CAS  PubMed  Google Scholar 

  • Glick ID, Correll CU, Altamura AC, Marder SR, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011;72:1616–27.

    Article  CAS  PubMed  Google Scholar 

  • Hargarter L, Cherubin P, Bergmans P, Keim S, et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry. 2015;58:1–7.

    Article  CAS  Google Scholar 

  • Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs. 2016;30:27–39.

    Article  CAS  PubMed  Google Scholar 

  • Hiemke C, Bergemann N, Clement HW, Conca A, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.

    Article  CAS  PubMed  Google Scholar 

  • Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jarema M, Bieńkowski P, Heitzman J, Parnowski T, Rybakowski J. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia. Psychiatr Pol. 2017;51:7–21.

    Article  PubMed  Google Scholar 

  • Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev. 2007:CD005040.

    Google Scholar 

  • Kim SW, Chung YC, Lee YH, Lee JH, et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol. 2012;27:267–74.

    Article  PubMed  Google Scholar 

  • Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74:568–75.

    Article  CAS  PubMed  Google Scholar 

  • Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011:CD006626.

    Google Scholar 

  • Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–71.

    Article  CAS  PubMed  Google Scholar 

  • Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004;65:1084–9.

    Article  CAS  PubMed  Google Scholar 

  • Mc Evoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014;311(19):1978–87.

    Article  PubMed  Google Scholar 

  • Möller HJ. Risperidone: a review. Expert Opin Pharmacother. 2005;6:803–18.

    Article  PubMed  Google Scholar 

  • Nielsen J, Jensen SO, Friis RB, Valentin JB, Correll CU. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2015;41:627–36.

    Article  PubMed  Google Scholar 

  • Nivoli AM, Murru A, Goikolea JM, Crespo JM, et al. New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord. 2012;140:125–41.

    Article  PubMed  Google Scholar 

  • Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012;6:CD008296.

    Google Scholar 

  • Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-Centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166:712–26.

    Article  CAS  PubMed  Google Scholar 

  • Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016;12:CD006918.

    PubMed  Google Scholar 

  • Sampson S, Hosalli P, Furtado VA, Davis JM. Risperidone (depot) for schizophrenia. Cochrane Database Syst Rev. 2016;4. Art No: CD004161.

    Google Scholar 

  • Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Exp Rev Clin Pharmacol. 2018;6:625–39.

    Article  Google Scholar 

  • Schotte A, Janssen PF, Megens AA, Leysen JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993;631:191–202.

    Article  CAS  PubMed  Google Scholar 

  • Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, et al. Paliperidone palmitate vs oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1–3):393–399.23.

    Article  PubMed  Google Scholar 

  • Subotnik KL, Casaus LR, Ventura J, Luo JS, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiat. 2015;72:822–9.

    Article  Google Scholar 

  • Taipale H, Mittendorf-Rutz E, Majak W, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197.

    Google Scholar 

  • Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiat. 2017;74:686–93.

    Article  Google Scholar 

  • Voss EA, Ryan PB, Stang PE, Hough D, Alphs L. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. Int Clin Psychopharmacol. 2015;30:151–157.29.

    Article  Google Scholar 

  • Wesołowska A, Jastrzębska-Więsek M, Cios A, Partyka A. The preclinical discovery and development of paliperidone for the treatment of schizophrenia. Exp Opin Drug Discov. 2020;15:279–92.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  2. MVZ Waldkraiburg, Center of Neuropsychiatry, Waldkraiburg, Germany

    Gerd Laux

  3. Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University (LMU), Munich, Germany

    Gerd Laux

Authors
  1. Gerd Laux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerd Laux .

Editor information

Editors and Affiliations

  1. Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Wuerzburg, Germany

    Peter Riederer

  2. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  3. Centre for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Germany

    Christian Riederer

Section Editor information

  1. Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany

    Frank Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Laux, G. (2022). Risperidone and Paliperone in the Treatment of Psychosis. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_473

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62059-2_473

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62058-5

  • Online ISBN: 978-3-030-62059-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation